ADA backs CGM wider
The 2026 ADA Standards now recommend continuous glucose monitoring for adults on insulin, those at risk of hypoglycaemia, or anyone who would benefit—CGM gives trend context that fingersticks miss. (incarenow.com) Wearable CGM plus AI analytics are being pitched as the operational backbone for proactive diabetes care in clinics and self‑management tools. (diabetesdaily.com)
The ADA published the Standards of Care in Diabetes—2026 on Dec. 8, 2025, and the update includes expanded technology guidance that explicitly broadens when clinicians should consider continuous glucose monitoring. (prnewswire.com) Randomized trials and systematic reviews used in the Standards show CGM use improves time-in-range and lowers HbA1c across type 1 and insulin-treated type 2 populations, forming the evidence base for the wider recommendation. ( ) Device makers and clinic software vendors are already pairing wearable CGMs with analytics platforms for population management: Dexcom markets Dexcom Clarity for clinics and announced a proprietary generative-AI initiative in late 2024 to generate individualized insights from CGM data. ( ) Academic teams are training large sensor models on pooled CGM datasets to forecast near-term glucose trajectories, with a September 2025 npj Health Systems paper describing a pretrained “foundation model” for CGM prediction. (nature.com) Payer and access context: CMS expanded Medicare CGM coverage in 2023 to any beneficiary prescribed insulin, increasing eligibility by roughly 1.5 million people, but ADA field research in 2025 found prior authorization and administrative barriers still delay patient access. ( ) Clinics adopting CGM-plus-AI models face workflow challenges—manufacturers warn their analytics tools are for pattern review and not for autonomous dosing decisions, and health-system reviews call for clinician “guard rails” to manage CGM data volume and AI recommendations. ( )
